The amount of the deal was not disclosed.
The acquisitions marks GE Healthcare’s continued investment in photon counting CT technology (PCCT) , which has the potential to establish a new standard of care in oncology, cardiology, neurology, and many other clinical CT applications. PCCT has the promise to further expand the clinical capabilities of traditional CT, including the visualization of minute details of organ structures, improved tissue characterization, more accurate material density measurement (or quantification) and lower radiation dose.
GE Healthcare expects to close the Prismatic Sensors acquisition by January 2021, after holding a minority position in the company since 2017. The two companies will work together to deliver a clinical system in the near future.
Founded in 2012 as a spin-off from KTH Royal Institute of Technology in Stockholm, Sweden, and led by Mats Danielsson, PhD, CEO, Prismatic Sensors is a spin-off company from research at KTH Royal Institute of Technology and Linköping Institute of Technology. The company is focused on research and development of photon counting detectors for CT, providing improved contrast and spatial resolution at reduced radiation dose. Prismatic has many granted patents as well as pending patent applications.